Paul L Nguyen1, Zaid Haddad2, Ashley E Ross3, Neil E Martin4, Samineh Deheshi2, Lucia L C Lam2, Jijumon Chelliserry2, Jeffrey J Tosoian3, Tamara L Lotan3, Daniel E Spratt5, Radka S Stoyanova6, Sanoj Punnen6, Kaye Ong2, Christine Buerki2, Maria Aranes2, Tyler Kolisnik2, Jennifer Margrave2, Kasra Yousefi2, Voleak Choeurng2, Elai Davicioni2, Bruce J Trock3, Christopher J Kane7, Alan Pollack6, John W Davis8, Felix Y Feng9, Eric A Klein10. 1. Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA. Electronic address: pnguyen@lroc.harvard.edu. 2. GenomeDx Biosciences Inc., Vancouver, BC, Canada. 3. James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD, USA. 4. Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA. 5. Department of Radiation Oncology, Michigan Center for Translational Pathology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA. 6. Department of Radiation Oncology, Miller School of Medicine University of Miami, Miami, FL, USA. 7. Department of Urology, University of California, San Diego, San Diego, CA, USA. 8. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 9. Department of Radiation Oncology, University of California at San Francisco, San Francisco, CA, USA. 10. Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract
BACKGROUND: Decipher is a validated genomic classifier developed to determine the biological potential for metastasis after radical prostatectomy (RP). OBJECTIVE: To evaluate the ability of biopsy Decipher to predict metastasis and Prostate cancer-specific mortality (PCSM) in primarily intermediate- to high-risk patients treated with RP or radiation therapy (RT). DESIGN, SETTING, AND PARTICIPANTS: Two hundred and thirty-five patients treated with either RP (n=105) or RT±androgen deprivation therapy (n=130) with available genomic expression profiles generated from diagnostic biopsy specimens from seven tertiary referral centers. The highest-grade core was sampled and Decipher was calculated based on a locked random forest model. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Metastasis and PCSM were the primary and secondary outcomes of the study, respectively. Cox analysis and c-index were used to evaluate the performance of Decipher. RESULTS AND LIMITATIONS: With a median follow-up of 6 yr among censored patients, 34 patients developed metastases and 11 died of prostate cancer. On multivariable analysis, biopsy Decipher remained a significant predictor of metastasis (hazard ratio: 1.37 per 10% increase in score, 95% confidence interval [CI]: 1.06-1.78, p=0.018) after adjusting for clinical variables. For predicting metastasis 5-yr post-biopsy, Cancer of the Prostate Risk Assessment score had a c-index of 0.60 (95% CI: 0.50-0.69), while Cancer of the Prostate Risk Assessment plus biopsy Decipher had a c-index of 0.71 (95% CI: 0.60-0.82). National Comprehensive Cancer Network risk group had a c-index of 0.66 (95% CI: 0.53-0.77), while National Comprehensive Cancer Network plus biopsy Decipher had a c-index of 0.74 (95% CI: 0.66-0.82). Biopsy Decipher was a significant predictor of PCSM (hazard ratio: 1.57 per 10% increase in score, 95% CI: 1.03-2.48, p=0.037), with a 5-yr PCSM rate of 0%, 0%, and 9.4% for Decipher low, intermediate, and high, respectively. CONCLUSIONS: Biopsy Decipher predicted metastasis and PCSM from diagnostic biopsy specimens of primarily intermediate- and high-risk men treated with first-line RT or RP. PATIENT SUMMARY: Biopsy Decipher predicted metastasis and prostate cancer-specific mortality risk from diagnostic biopsy specimens.
BACKGROUND: Decipher is a validated genomic classifier developed to determine the biological potential for metastasis after radical prostatectomy (RP). OBJECTIVE: To evaluate the ability of biopsy Decipher to predict metastasis and Prostate cancer-specific mortality (PCSM) in primarily intermediate- to high-risk patients treated with RP or radiation therapy (RT). DESIGN, SETTING, AND PARTICIPANTS: Two hundred and thirty-five patients treated with either RP (n=105) or RT±androgen deprivation therapy (n=130) with available genomic expression profiles generated from diagnostic biopsy specimens from seven tertiary referral centers. The highest-grade core was sampled and Decipher was calculated based on a locked random forest model. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Metastasis and PCSM were the primary and secondary outcomes of the study, respectively. Cox analysis and c-index were used to evaluate the performance of Decipher. RESULTS AND LIMITATIONS: With a median follow-up of 6 yr among censored patients, 34 patients developed metastases and 11 died of prostate cancer. On multivariable analysis, biopsy Decipher remained a significant predictor of metastasis (hazard ratio: 1.37 per 10% increase in score, 95% confidence interval [CI]: 1.06-1.78, p=0.018) after adjusting for clinical variables. For predicting metastasis 5-yr post-biopsy, Cancer of the Prostate Risk Assessment score had a c-index of 0.60 (95% CI: 0.50-0.69), while Cancer of the Prostate Risk Assessment plus biopsy Decipher had a c-index of 0.71 (95% CI: 0.60-0.82). National Comprehensive Cancer Network risk group had a c-index of 0.66 (95% CI: 0.53-0.77), while National Comprehensive Cancer Network plus biopsy Decipher had a c-index of 0.74 (95% CI: 0.66-0.82). Biopsy Decipher was a significant predictor of PCSM (hazard ratio: 1.57 per 10% increase in score, 95% CI: 1.03-2.48, p=0.037), with a 5-yr PCSM rate of 0%, 0%, and 9.4% for Decipher low, intermediate, and high, respectively. CONCLUSIONS: Biopsy Decipher predicted metastasis and PCSM from diagnostic biopsy specimens of primarily intermediate- and high-risk men treated with first-line RT or RP. PATIENT SUMMARY: Biopsy Decipher predicted metastasis and prostate cancer-specific mortality risk from diagnostic biopsy specimens.
Authors: Daniel E Spratt; Jingbin Zhang; María Santiago-Jiménez; Robert T Dess; John W Davis; Robert B Den; Adam P Dicker; Christopher J Kane; Alan Pollack; Radka Stoyanova; Firas Abdollah; Ashley E Ross; Adam Cole; Edward Uchio; Josh M Randall; Hao Nguyen; Shuang G Zhao; Rohit Mehra; Andrew G Glass; Lucia L C Lam; Jijumon Chelliserry; Marguerite du Plessis; Voleak Choeurng; Maria Aranes; Tyler Kolisnik; Jennifer Margrave; Jason Alter; Jennifer Jordan; Christine Buerki; Kasra Yousefi; Zaid Haddad; Elai Davicioni; Edouard J Trabulsi; Stacy Loeb; Ashutosh Tewari; Peter R Carroll; Sheila Weinmann; Edward M Schaeffer; Eric A Klein; R Jeffrey Karnes; Felix Y Feng; Paul L Nguyen Journal: J Clin Oncol Date: 2017-11-29 Impact factor: 44.544
Authors: Deli Liu; Michael A Augello; Ivana Grbesa; Davide Prandi; Yang Liu; Jonathan E Shoag; R Jeffrey Karnes; Bruce J Trock; Eric A Klein; Robert B Den; Francesca Demichelis; Elai Davicioni; Andrea Sboner; Christopher E Barbieri Journal: J Clin Invest Date: 2021-05-17 Impact factor: 14.808
Authors: Daniel E Spratt; Darlene L Y Dai; Robert B Den; Patricia Troncoso; Kasra Yousefi; Ashley E Ross; Edward M Schaeffer; Zaid Haddad; Elai Davicioni; Rohit Mehra; Todd M Morgan; Walter Rayford; Firas Abdollah; Edouard Trabulsi; Mary Achim; Elsa Li Ning Tapia; Mireya Guerrero; Robert Jeffrey Karnes; Adam P Dicker; Mark A Hurwitz; Paul L Nguyen; Felix F Y Feng; Stephen J Freedland; John W Davis Journal: Eur Urol Date: 2017-12-10 Impact factor: 20.096
Authors: Thomas M Pisansky; Ian M Thompson; Richard K Valicenti; Anthony V D'Amico; Shalini Selvarajah Journal: J Urol Date: 2019-08-08 Impact factor: 7.450
Authors: Timothy N Clinton; Aditya Bagrodia; Yair Lotan; Vitaly Margulis; Ganesh V Raj; Solomon L Woldu Journal: Expert Rev Precis Med Drug Dev Date: 2017-09-05
Authors: Spyridon P Basourakos; Michael Tzeng; Patrick J Lewicki; Krishnan Patel; Bashir Al Hussein Al Awamlh; Siv Venkat; Jonathan E Shoag; Michael A Gorin; Christopher E Barbieri; Jim C Hu Journal: Front Oncol Date: 2021-05-28 Impact factor: 6.244
Authors: Belén Pastor-Navarro; José Rubio-Briones; Ángel Borque-Fernando; Luis M Esteban; Jose Luis Dominguez-Escrig; José Antonio López-Guerrero Journal: Int J Mol Sci Date: 2021-06-10 Impact factor: 5.923